|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
8/14/2007 3:46:09 PM
EMERYVILLE, CA (August 14, 2007) -- Omicia, Inc., a privately held company specializing in personalized genetic signatures for early detection of disease risk, has been awarded its fourth NIH grant, a $182,732 Small Business Technology Transfer (STTR) Phase I grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health. This industry/academia collaboration between Omicia and Johns Hopkins University (JHU) will be headed by Principal Investigator Dr. Joel Bader, an Assistant Professor of Biomedical Engineering at JHU. Drawing upon Omicias advanced understanding of disease genes and phenotypes and Dr. Baders expertise in gene interaction networks and model organism genetics, the project will identify genes whose variants increase the risk of developing cardiovascular disease.
|
|
|
|
|
|
|
|
|
|
|